潮汐海灵
A multicenter, open-label pha II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapd and refractory生活中不缺少美>三八活动方案
multiple myeloma.
期刊名称： American Journal of Hematology
年份： 2014年
期号： 第11期
关键词： Recombinant human circularly permuted TRAIL;Multiple
myeloma;Thalidomide;Combination therapy
fly名词摘要：Circularly permuted TRAIL (CPT), a recombinant mutant of human Apo2L/TRAIL, is a novel antitumor candidate for multiple myeloma (MM) and other hematologic malignancies. In this pha II study, the safety and efficacy of CPT plus thalidomide was investigated in thalidomide-resistant MM patients. A total of 43
patients were recruited into three CPT plus thalidomide cohorts bad on CPT我要网
事件通讯dosage in quence: 5 mg/kg (n=11), 8 mg/kg (n=17), and 10 mg/kg (n=15). CPT
was administered via intravenous infusion on days 1-5, and thalidomide was given
orally at 100 mg once daily in each 21-day cycle. The overall respon rate (ORR) of全民阅读活动
41 efficacy-evaluable patients was 22.0% (2 complete respon, 3 near complete
respon, and 4 partial respon). No significant difference in the ORR was
李密简介
obrved among the three do cohorts; however, the
内容由中国教育图书进出口有限公司引进
